Cardiomyopathy |
|
|
Clinical Trial: Mapping Novel Disease Genes for Dilated Cardiomyopathy
This study is no longer recruiting patients.
Purpose
To identify new dilated cardiomyopathy genes by genetic linkage and mutational analyses.
| Condition |
|---|
| Cardiomyopathy, Congestive Cardiovascular Diseases Heart Diseases Heart Failure, Congestive |
MedlinePlus related topics: Cardiomyopathy; Heart Diseases; Heart Diseases--Prevention; Heart Failure; Vascular Diseases
Study Type: Observational
Study Design: Natural History
Study start: July 2002; Study completion: June 2005
BACKGROUND: Dilated cardiomyopathy (DCM) is a heritable, genetically heterogeneous disorder causing congestive heart failure. Current medical therapy has minimal impact on prognosis and cardiac transplantation is the only definitive treatment for end-stage disease. The molecular and cellular mechanisms underlying DCM are poorly defined, but the importance of single gene defects in disease pathogenesis is becoming increasingly apparent.
DESIGN NARRATIVE: The genetic epidemiology study will identify novel dilated cardiomyopathy genes using genetic linkage and mutational analyses. The first aim is to determine the chromosomal location of novel familial dilated cardiomyopathy genes. This will be accomplished by genome-wide genotyping and genetic linkage analyses in three large families with autosomal dominant dilated cardiomyopathy. Previously identified dilated cardiomyopathy genes have been excluded in these families. The second aim is to identify mutations in novel genes that cause familial dilated cardiomyopathy by linkage and sequence analyses of candidate genes mapping to dilated cardiomyopathy loci. Once novel genes for familial dilated cardiomyopathy are identified, the third aim will be to determine the role of these genes in a large cohort of unrelated patients with familial and sporadic dilated cardiomyopathy. High throughput DNA sequence analyses will be performed to identify additional inherited and de novo mutations.
Eligibility
Genders Eligible for Study: Both
Criteria
Location Information
Timothy Olson, Mayo Clinic
More Information
Publications
Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC, Rodeheffer RJ, Anderson JL. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005 Jan 26;293(4):447-54.
Record last reviewed: January 2005
Last Updated: February 3, 2005
Record first received: September 30, 2002
ClinicalTrials.gov Identifier: NCT00046618
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


